

Information Governance

12 April 2017

**Our Ref:** RFI 19893

Dear

**Freedom of Information Act 2000  
Information in Relation to Treatment of Lung Cancer within the Last 6  
Months**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for the information relating to the above which you requested on 14 March 2017.

A response to each of the questions raised has been provided by Hospital Services Directorate and is attached in Appendix A.

Under the terms of the legislation, if you are unhappy with this response you have the right to seek a review within the Trust in the first instance. If you wish to do so, please write to me at the address below.

If after such a review you are still unhappy with the response, you have the right to appeal to the Information Commissioner who will undertake an independent review. The Information Commissioner can be contacted at The Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, SK9 5AF.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

---

**L McAree (Miss)  
Head of Information Governance &  
Directorate Support**

- Q1. *Within your health trust how many patients are currently [within the past 6 months] being treated with a chemotherapy agent [not including surgery/radiotherapy only];*
- *All Non-Small Cell Lung Cancer patients*
  - *Patients with Non-Small Cell Lung Cancer (NSCLC) Stage IIIB\*\*/IV\*\* (Stage 3b/4)*

A1. 16 patients – all non-small cell lung cancer.  
The staging for these patients is not coded/broken down on the information system.

- Q2. *Of the NSCLC patients, please state the number of patients currently [within the past 6 months] being treated with the following therapies;*

A2. Please see Table 1 below completed as requested:-

**Table 1**

<b>Number of Patients</b>	<b>Treatment</b>
0	Afatinib (Giotrif)
0	Ceritinib (Zykadia)
1	Crizotinib (Xalkori)
0	Erlotinib (Tarceva)
1	Gefitinib (Iressa)
0	Nitendaninb + docetaxel
0	Nivolumab (Opdivo)
5	Pemetrexed (Alimta) mono or in combination with carboplatin / cisplatin
0	Pembrolizumab (Keytruda)
7	Gemcitabine mono or in combination with carboplatin / cisplatin
0	Paclitaxel mono or in combination with carboplatin / cisplatin
2	Doxetaxel mono or in combination with carboplatin / cisplatin
2	Vinorelbine [or other Vinka alkaloid] mono or in combination with carboplatin / Cisplatin

- Q3. *If your trust does not treat these cancers and you refer your patients to another trust, please state which trust?*

A3. Not applicable.

- Q4. *Within your health trust how many patients are currently [within the past 6 months] diagnosed with Urothelial cancer?*

A4. For the period 01/08/2016 and 31/01/2017 27 patients were diagnosed with bladder or ureter cancer.

*All Urothelial cancer (UCC, also transitional cell carcinoma or TCC) patients (TREATED or UNTREATED);*

*Metastatic\* or locally advanced\* Urothelial cancer (UCC, also transitional cell carcinoma or TCC) patients.*

Q5. *Of these patients (metastatic/locally advanced UCC), please state the number of patients currently [within the past 6 months] being treated with the following therapies;*

A5. Please see completed Table 2 below as requested:-

**Table 2**

<b>Treatment</b>	<b>Number of Patients</b>
Cisplatinium single agent	0
Cisplatinium in combination with another agent	0
Carboplatinium single agent	0
Carboplatinium in combination with another agent	5
Any other chemo regimen without cisplatinium or carboplatinium	0

*\*TNM staging for metastatic Urothelial Cancer = Any T, any N, M1*

*\*TNM staging for locally advanced Urothelial Cancer = Any T, N2-3, M0 or T4b, any N, M0*

*\*\*TNM staging for Stage IIIB NSCLC = Any T, N3, M0 or T4, N2, M0*

*\*\*TNM staging for Stage IV NSCLC = Any T, any N, M1*